Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder (NGF)

Bakirkoy Dr. Sadi Konuk Training and Research Hospital

Status: Unknown

Conditions: Overactive Bladder

Study type: Observational

Funder types: Other

Identifiers

NCT02335853

2014/11/02

Details and patient eligibility

About

Nerve growth factor (NGF-R) receptors are between the detrusor muscle fibers and can cause afferent signals. Metabolic syndrome and obesity have been advocated to be risk factors for the development of overactive bladder.

Full description

Overactive bladder is a clinical syndrome characterized urgency, frequency and nocturia. Infection or other obvious causes must be excluded. The overactive bladder is loss of inhibition of the detrusor muscle during the filling or emptying of the bladder.

Specific receptors and neurotransmitters have role in development of overactive bladder. These includes adrenergic, cholinergic, non-adrenergic, non-cholinergic receptors and interstitial cells.

Nerve growth factor (NGF-R) receptors are between the detrusor muscle fibers and can cause afferent signals. Metabolic syndrome and obesity have been advocated to be risk factors for the development of overactive bladder. The investigators believe that our findings will shed light on treatment.

Enrollment: 90 estimated patients

Sex: Female

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• women with urgency, nocturia and frequency
• Abdominal obesity, defined as a waist circumference in men ≥88 cm
• Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides
• Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C
• Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure
• Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose

Exclusion criteria

• Chronic obstructive pulmonary disease allergy
• Psychiatric disorders
• Urinary tract infection
• Neurological diseases
• Metabolic diseases
• Pure stress or mixed urinary incontinence
• History of pelvic surgery
• Diabetes mellitus

Trial design

90 participants in 3 patient groups

women with metabolic syndrome and overactive bladder

Description:

women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits: 1. Abdominal obesity, defined as a waist circumference in men ≥88 cm 2. Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides 3. Serum HDL cholesterol \<40 mg/dL (1 mmol/L) in men and \<50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C 4. Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure 5. Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose

women with overactive bladder

Description:

women with urinary urgency+frequency+nocturia

healthy control group

Description:

women not overactive bladder and metabolic syndrome